Inventor · disambiguated record
Kenneth V. Lawson
Also filed as: LAWSON KENNETH V · LAWSON KENNETH VICTOR
18 granted patents·5 pending applications·73 citations·filing 2017–2024
92Inventor score
Files withARCUS BIOSCIENCES INC23
Top patents by PatentIndex Score
23 records- 0198US11001603B2Modulators of 5′-nucleotidase, ecto and the use thereofARCUS BIOSCIENCES INC·Filed 2020·Granted May 11, 2021·13 cites·1 claims
- 0296US11633416B1Oral formulations of CD73 compoundsARCUS BIOSCIENCES INC·Filed 2021·Granted Apr 25, 2023·4 cites·24 claims
- 0396US10239912B2Modulators of 5′-nucleotidase, ecto and the use thereofARCUS BIOSCIENCES INC·Filed 2017·Granted Mar 26, 2019·23 cites·47 claims
- 0495US11667662B2Modulators of 5′-nucleotidase, ecto and the use thereofARCUS BIOSCIENCES INC·Filed 2021·Granted Jun 6, 2023·4 cites·9 claims
- 0595US10981944B2Modulators of 5′-nucleotidase, ecto and the use thereofARCUS BIOSCIENCES INC·Filed 2019·Granted Apr 20, 2021·11 cites·20 claims
- 0694US12168023B2Inhibitors of adenosine 5′-nucleotidaseARCUS BIOSCIENCES INC·Filed 2024·Granted Dec 17, 2024·1 cites·24 claims
- 0794US11787762B2Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alphaARCUS BIOSCIENCES INC·Filed 2022·Granted Oct 17, 2023·2 cites·26 claims
- 0893US11407712B2Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2αARCUS BIOSCIENCES INC·Filed 2021·Granted Aug 9, 2022·3 cites·15 claims
- 0992US12145901B1Process for preparing tetralin compoundsARCUS BIOSCIENCES INC·Filed 2022·Granted Nov 19, 2024·2 cites·25 claims
- 1091US11819512B2Solid forms of a CD73 inhibitor and the use thereofARCUS BIOSCIENCES INC·Filed 2019·Granted Nov 21, 2023·5 cites·17 claims
- 1186US12459967B2Modulators of 5′-nucleotidase, ecto and the use thereofARCUS BIOSCIENCES INC·Filed 2023·Granted Nov 4, 2025·0 cites·11 claims
- 1286US12103907B2Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alphaARCUS BIOSCIENCES INC·Filed 2023·Granted Oct 1, 2024·0 cites·1 claims
- 1385US11058704B2Inhibitors of adenosine 5′-nucleotidaseARCUS BIOSCIENCES INC·Filed 2017·Granted Jul 13, 2021·4 cites·25 claims
- 1483US2025319113A1Inhibitors of adenosine 5'-nucleotidaseARCUS BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 1582US2025214930A1Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2alphaARCUS BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 1679US11267845B2Inhibitors of CD73-mediated immunosuppressionARCUS BIOSCIENCES INC·Filed 2017·Granted Mar 8, 2022·1 cites·32 claims
- 1762US2025011318A1Cbl-b inhibitors and methods of use thereofARCUS BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 1862US2024425497A1Cbl-b Inhibitors and Methods of Use ThereofARCUS BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 1960US12071411B2Inhibitors of HIF-2α and methods of use thereofARCUS BIOSCIENCES INC·Filed 2022·Granted Aug 27, 2024·0 cites·31 claims
- 2052US11931343B2CD73 inhibitorsARCUS BIOSCIENCES INC·Filed 2019·Granted Mar 19, 2024·0 cites·11 claims
- 2151US2023024438A1Inhibitors of hif-2alphaARCUS BIOSCIENCES INC·Filed 2020·Application pending·0 cites
- 2249US12433836B2Parenterally administered immune enhancing drugsARCUS BIOSCIENCES INC·Filed 2019·Granted Oct 7, 2025·0 cites·27 claims
- 2345US12410170B22,3,5-trisubstituted pyrazolo[1,5-A]pyrimidine compoundsARCUS BIOSCIENCES INC·Filed 2020·Granted Sep 9, 2025·0 cites·13 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →